SAN ANTONIO, Sept. 21, 2015 (GLOBE NEWSWIRE) -- Fountainhead Investment Partners is announcing its transition from an angel fund to a venture capital firm to provide a broader path for early-stage company support. The angel fund is now closed with $1 million in committed capital and will be managed by Fountainhead Investment Partners.
“The decision to evolve from an angel fund to a venture capital firm became clear to us based on the interest level we received from both investors and the number of potential portfolio companies we are finding that fit within our unique investment strategy,” said Brian Kieser, Fountainhead Managing Partner. “There are a lot of compelling opportunities to put investor capital to work and this gives us a better format to make those investments.”
Founded in 2014 as an angel fund, Fountainhead Investment Partners’ vision remains the same — to connect advancing technologies in order to solve some of medicines’ most complex issues. Fountainhead will continue to focus its initial investments in areas of medical devices, surgical tools, multicellular biologics, regenerative technologies, medical knowledge management and 3D printing. Investments ranging from $250,000 to $1 million will be made in early-stage companies.
Fountainhead’s initial portfolio company investment was in the AmnioLife Corporation, a human cells, tissues, and cellular-based products developer, based in Gainesville, Fla. The firm led AmnioLife’s Series A funding round of $833,000 with an investment of $750,000.
“The angel fund was an ideal way to validate our investment strategy, and the response is really promising,” said Kieser. “We look forward to applying that strategy to a larger portfolio and creating the infrastructure that supports an accelerated path for success.”
About Fountainhead Investment Partners
Fountainhead Investment Partners is a venture capital firm that invests in early-stage companies. Fountainhead was originally founded as an angel fund in 2014 by a group of successful healthcare entrepreneurs with a vision to connect advancing technologies in order to solve some of medicines’ most complex issues.
In 2015, Fountainhead transitioned to a venture capital firm, with initial funds focused on companies that are accessing innovative technologies from all industries and applying them to the science of medicine with the intention of disrupting the industry while also advancing patient care.
Fountainhead makes portfolio investments ranging from $250,000 to $1 million. Partners work side-by-side with portfolio companies on operations strategies and management guidance in order to maximize the highest potential growth.